TapImmune Inc. Announces Agreement With AppTec

VANCOUVER, British Columbia, Aug. 16, 2007 (PRIME NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIM) (Germany:GX1A), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced a contractual agreement with AppTec, headquartered in St. Paul, Minnesota, for the preclinical testing of its lead product. The immunotherapy vaccine is designed to treat a wide variety of carcinomas that include lung cancers, liver cancers, kidney cancers, head and neck cancers, breast cancers, melanomas, prostate cancers, colorectal cancers, and cervical cancers. This is the first stage in moving the Company's proprietary vaccine from the research laboratory into clinical investigation.